Capital Building in Washington DC

Advocacy & Policy

To improve patient care, ASCO advocates for increased federal funding for research, greater health care access, value in cancer care, and payment reform.

  • NCI Increases Funding for National Clinical Trials Network

    ASCO applauds the announcement by National Cancer Institute (NCI) Director, Dr. Norman Sharpless, at the 2018 ASCO Annual Meeting to provide $10 million in new funding for the National Clinical Trials Network.

    Read More
  • Right-to-Try or Right-to-Ask?

    Right-to-try (RTT) is the latest topic addressed on the ASCO in Action Podcast. ASCO CEO, Dr. Clifford A. Hudis, sits down with Senior VP and CMO Dr. Richard Schilsky to examine RTT legislation.

    Listen Now
  • ASCO Urges Action on Cancer Policy Priorities at AMA Meeting

    ASCO delegates recently participated in the American Medical Association’s (AMA) Annual Meeting of the House of Delegates. During the meeting, ASCO delegates introduced resolutions on opioid prescription transfers, pharmacy benefit managers, and the 340B drug discount program.

    Learn More

Random Quote

"ASCO is the world’s largest and arguably most influential oncology organization… a dynamic organization that not only is advancing the frontiers of research, providing outstanding educational opportunities, and defining standards of practice for clinical care, but also influencing public policy."
Anees Chagpar, MD
ASCO Member since 2003